Research classified by
Journal of
Economic Literature (JEL) codes
Top JEL
/
L: Industrial Organization
/ /
L6: Industry Studies: Manufacturing
/ / /
L65: Chemicals; Rubber; Drugs; Biotechnology
This topic is covered by the following reading lists:- Industrial Sociology (FCT-UNL)
Most recent items first, undated at the end.
2013 Inter-firm R&D networks in pharmaceutical biotechnology: What determines firm's centrality-based partnering capability
by Krogmann, Yin & Riedel, Nadine & Schwalbe, Ulrich
2013 La chimie verte: une nouvelle industrie de substitution GREEN CHEMISTRY: A NEW INDUSTRY OF SUBSTITUTE
by Clément WILS
2013 Proximity, network formation and inventive performance: in search of the proximity paradox
by Cassi, Lorenzo & Plunket, Anne
2013 Explorative Versus Exploitative Alliances—Evidence From The Glass Industry In China
by Leung, Vincent K.K. & Lau, Chi Keung Marco & Zhang, Zhe
2013 Price Indexes for Clinical Trial Research: A Feasibility Study
by Ernst R. Berndt & Iain M. Cockburn
2013 Behind the Scenes: Sources of Complementarity in R&D
by Marco Ceccagnoli & Matthew J. Higgins & Vincenzo Palermo
2013 Drug launch timing and international reference pricing
by Nicolas Houy & Izabela Jelovac
2013 Drug launch timing and international reference pricing
by Nicolas Houy & Izabela Jelovac
2013 Scientific Knowledge Dynamics and Relatedness in Bio-Tech Cities
by Ron Boschma & Gaston Heimeriks & Pierre-Alexandre Balland
2013 Determinants of Generic vs. Brand Drug Choice: Evidence from Population-wide Danish Data
by Niels Skipper & Rune Vejlin
2013 Competition in the pharmaceutical industry: How do quality differences shape advertising strategies?
by de Frutos, Maria-Angeles & Ornaghi, Carmine & Siotis, Georges
2013 Informing the uninformed: How drug advertising affects check-up visits
by Hosken, Daniel & Wendling, Brett
2013 Direct-to-consumer advertising and consumer welfare
by Jayawardhana, Jayani
2013 Margins and market shares: Pharmacy incentives for generic substitution
by Brekke, Kurt Richard & Holmås, Tor Helge & Straume, Odd Rune
2013 Margins and market shares: Pharmacy incentives for generic substitution
by Brekke, Kurt Richard & Holmås, Tor Helge & Straume, Odd Rune
2013 Mandatory disclosure of plant emissions into the environment and worker chemical exposure inside plants
by Finger, Stephen R. & Gamper-Rabindran, Shanti
2013 Can Financial Engineering Cure Cancer?
by David E. Fagnan & Jose Maria Fernandez & Andrew W. Lo & Roger M. Stein
2012 Sources of Heterogeneity in the Efficiency of Indian Pharmaceutical Firms
by MAZUMDAR, MAINAK & RAJEEV, MEENAKSHI & RAY, SUBHASH C.
2012 Launching prices for new pharmaceuticals in heavily regulated and subsidized markets
by Jaume Puig & Beatriz González López-Valcárcel
2012 Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010
by Berndt, Ernst & Dubois, Pierre
2012 The Role of the South African Government in Developing the Biotechnology Industry – from Biotechnology Regional Innovation Centres to the Technology Innovation Agency
by Ramazan Uctu & Hassan Essop
2012 Engineering Knowledge
by Nathan Rosenberg & W. Edward Steinmuller
2012 How Do The Institutions Involved In Scientific Collaboration Deal With Different Kinds Of Distance? An Analysis Of The Co-Autorships Of Scientific Publications
by Rosamaria D’Amore & Roberto Iorio & Sandrine Labory & Agnieszka Stawinoga
2012 Who And Where Are The Co-Authors? The Relationship Between Institutional And Geographical Distance In Scientific Publications
by Rosamaria D’Amore & Roberto Iorio & Agnieszka Stawinoga
2012 Le rôle de l’Etat dans la promotion du secteur pharmaceutique en Algérie: que nous enseigne l’approche par les systèmes sectoriels d’innovation THE ROLE OF THE STATE IN THE PROMOTION OF THE PHARMACEUTICAL SECTOR IN ALGERIA: WHAT DOES THE SECTORAL SYSTEMS OF INNOVATION APPROACH TEACH US?
by Samia GHARBI
2012 Competitiveness and future challenges of Pohjois-Savo - A report for The Regional Council of Pohjois-Savo (in Finnish with English abstract and summary)
by Hernesniemi, Hannu & Kulvik, Martti & Ylä-Anttila, Pekka
2012 Research collaboration in co-inventor networks: combining closure,bridging and proximities
by Cassi, Lorenzo & Plunket, Anne
2012 Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry
by Anderson, Simon & Ciliberto, Federico & Liaukonyte, Jura & Renault, Regis
2012 The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans Evidence from the 2004 National Nursing Home Survey
by Frank R. Lichtenberg
2012 R&D for Neglected Diseases
by Nicola Dimitri
2012 Entry Time Effects and Follow-on Drugs Competition
by Luiz Flavio Andrade
2012 Déterminants de l’écart de prix entre médicaments similaires et le premier entrant d’une classe thérapeutique
by Christine Sorasith & Sylvain Pichetti & Thomas Cartier & Laure Bergua & Catherine Sermet
2012 Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010
by Berndt, Ernst & Dubois, Pierre
2012 The effect of pharmacies’ right to negotiate discounts on the market share of parallel imported pharmaceuticals
by Granlund, David
2012 The effect of pharmacies’ right to negotiate discounts on the market share of parallel imported pharmaceuticals
by Granlund, David
2012 EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals - What’s to Blame? Derogation or Perception?
by Granlund, David & Yesim Köksal, Miyase
2012 Regional trajectories of innovation in Green Chemistry: Evidence from the Aquitaine region (In French)
by Vanessa OLTRA & Maïder SAINT-JEAN
2012 Mapping the scientific knowledge of the Green Chemistry community (In French)
by Marianna EPICOCO (GREThA, CNRS, UMR 5113) & Vanessa OLTRA (GREThA, CNRS, UMR 5113) & Maïder SAINT JEAN (GREThA, CNRS, UMR 5113)
2012 Generic substitution policy, prices and market structure: evidence from a quasi-experiment in Finland
by Aki Kangasharju & Joni Hokkanen & Ismo Linnosmaa & Hannu Valtonen
2012 The path- and place-dependent nature of scientific knowledge production in biotech 1986-2008
by Gaston Heimeriks & Ron Boschma
2012 Path-breaking innovations for lung cancer: a revolution in clinical practice
by Mario Coccia
2012 Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010
by Berndt, Ernst R & Dubois, Pierre
2012 Push-Me Pull-You: Comparative Advertising in the OTC Analgesics Industry
by Anderson, Simon P & Ciliberto, Federico & Liaukonyte, Jura & Renault, Régis
2012 The rising Chinese pharmaceutical industry: local champions vs global players
by Francesca Spigarelli & Hao Way
2012 Margins and Market Shares: Pharmacy Incentives for Generic Substitution
by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume
2012 The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data
by Frank Lichtenberg & Billie Pettersson
2012 Launching Prices for New Pharmaceuticals in Heavily Regulated and Subsidized Markets
by Jaume Puig-Junoy & Beatriz Gonzalez L�pez-Valc�rcel
2012 Investments in Pharmaceuticals Before and After TRIPS
by Margaret K. Kyle & Anita M. McGahan
2012 Quasi-fixed inputs in the Italian manufacturing: The case of the pharmaceutical industry
by Carbonari, Lorenzo
2012 Research Collaboration and Publication's Citation Impact: Evidence in the Italian Biotech Sector
by Roberto IORIO & Sandrine LABORY & Daniele PACI
2012 Energy saving opportunities in Jordanian pharmaceutical industries
by Mohammad Al-Tahat & Areen Al-Ali
2012 Entry and submarket concentration: empirical evidence from the pharmaceutical industry
by Maria Letizia Giorgetti
2012 Human resource management for learning through knowledge exploitation and knowledge exploration: Pharmaceuticals in Mexico
by Santiago, Fernando & Alcorta, Ludovico
2012 The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry
by Toole, Andrew A.
2012 What do drug monopolies cost consumers in developing countries?
by Hellerstein, Rebecca
2012 Productivity Growth in Some Energy Intensive Manufacturing Industries in India: An Analytical Assessment
by Sarbapriya Ray
2012 Drug Innovations and Welfare Measures Computed from Market Demand: The Case of Anti-cholesterol Drugs
by Abe Dunn
2012 The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors
by Craig L. Garthwaite
2011 The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry
by Toole, Andrew A.
2011 Inter-firm R&D networks in the global pharmaceutical biotechnology industry during 1985 - 1998: A conceptual and empirical analysis
by Krogmann, Yin & Schwalbe, Ulrich
2011 Generic drugs in Spain: price competition vs. moral hazard
by Ivan Moreno-Torres
2011 What if there was a stronger pharmaceutical price competition in Spain? When regulation has a similar effect to collusion
by Ivan Moreno-Torres
2011 Sources of Heterogeneity in the Efficiency of Indian Pharmaceutical Firms
by Mainak Mazumdar & Meenakshi Rajeev & Subhash Ray
2011 Market Size and Pharmaceutical Innovation
by Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul
2011 Innovation and Corporate Dynamics: A Theoretical Framework
by Jakub Growiec & Fabio Pammolli & Massimo Riccaboni
2011 A Few Special Cases: Scientific Creativity and Network Dynamics in the Field of Rare Diseases
by Massimo Riccaboni & Maria Laura Frigotto
2011 Determinants of drug launch delay in pre-TRIPS India: A survival analysis approach
by Saradindu Bhaduri & Thomas Brenner
2011 Gravity and extended gravity: estimating a structural model of export entry
by Morales, Eduardo & Sheu, Gloria & Zahler, Andrés
2011 Innovation and Corporate Dynamics: A Theoretical Framework
by Massimo, Riccaboni & Jakub, Growiec & Fabio, Pammolli
2011 Trade and Innovation: Pharmaceuticals
by Nobuo Kiriyama
2011 External referencing and pharmaceutical price negociation
by Garcia Marinoso, Begona & Jelovac, Izabella & Olivella, Pau
2011 Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets
by Patricia M. Danzon & Michael F. Furukawa
2011 A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets
by Ernst R. Berndt & Thomas G. McGuire & Joseph P. Newhouse
2011 Explaining vertical integration in the generic pharmaceutical industry
by Kensuke Kubo
2011 Market Size and Pharmaceutical Innovation
by Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul
2011 EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals - What’s to Blame? Derogation or Perception?
by Granlund, David & Yesim Köksal, Miyase
2011 Parallel Imports and Mandatory Substitution Reform - A Kick or A Muff for Price Competition in Pharmaceuticals?
by Granlund, David & Köksal , Miyase Yesim
2011 Parallel Imports and Mandatory Substitution Reform - A Kick or A Muff for Price Competition in Pharmaceuticals?
by Granlund, David & Köksal, Miyase Yesim
2011 Subjective well-being among preadolescents - Evidence from urban China
by Carlsson, Fredrik & Lampi, Elina & Li, Wanxin & Martinsson, Peter
2011 EU Enlargement, Parallel Trade and Price Competition in Pharmaceuticals. What's blame? Derogation or perception?
by Granlund, David & Yesim Köksal, Miyase
2011 Parallel Imports and Mandatory Substitution Reform: A kick or a muff for price competition in pharmaceuticals
by Granlund, David & Yesim Köksal, Miyase
2011 The Dynamics of the Inventor Network in German Biotechnology: Geographical Proximity versus Triadic Closure
by Anne L.J. Ter Wal
2011 Global Framework for Differential Pricing of Pharmaceuticals
by Daems, Rutger & Maes, Edith & Ramani, Shyama V.
2011 Mapping the interdisciplinary nature and co-evolutionary patterns in five nano-industrial sectors
by Wang, Lili & Notten, Ad
2011 On the institutional innovation process : EU regulation through an evolutionary lens
by Evita Paraskevopoulou
2011 Investments in Pharmaceuticals Before and After TRIPS
by Kyle, Margaret K & McGahan, Anita M
2011 Market Size and Pharmaceutical Innovation
by de Mouzon, Oliver & Dubois, Pierre & Scott Morton, Fiona & Seabright, Paul
2011 Inefficiencies in technology transfer: theory and empirics
by Allain, Marie-Laure & Henry, Emeric & Kyle, Margaret K
2011 Multiscalar Clusters And Networks As The Foundations Of Innovation Dynamics In The Biopharmaceutical Industry
by Marc-Hubert DEPRET & Abdelillah HAMDOUCH
2011 An Application of Economic Capacity Utilization to the Measurement of Total Factor Productivity Growth: Empirical Evidence from Indian Fertilizer Industry
by Sarbapriya, Ray & Mihir, Kumar Pal
2011 Growth and Financing Behaviour of Firms of Textile Industry in Pakistan: A Panel Data Analysis
by Ijaz Hussain
2011 The Production Of Medicines In Romania After 1990. What'S The Reason For Imports?
by Unita Lucian & Straciuc Oreste & Maghiar Teodor Traian & Uivarosan Diana
2011 Strategic Development Trends in the World Pharmaceutical Industry
by Dragan Kesic
2011 Spatial collocation and venture capital in the US biotechnology industry
by Kolympiris, Christos & Kalaitzandonakes, Nicholas & Miller, Douglas
2011 Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment
by Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune
2011 Too Many Products: Decentralized Decision Making in Multinational Firms
by Catherine Thomas
2011 Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration
by Glenn Ellison & Sara Fisher Ellison
2010 The impact of pricing and patent expiration on the demand for pharmaceuticals: An examination of the use of broad-spectrum antimicrobials
by Kaier, Klaus
2010 Opportunities and Benefits as Determinants of the Direction of Scientific Research
by Mikko Packalen & Jay Bhattacharya
2010 Child Externalising and Internalising Behaviour in the First Year of School: The Role of Parenting in a Low SES Population
by Carly Cheevers & Orla Doyle & Kelly McNamara
2010 Decomposing Gender Differences in College Student Earnings Expectations
by Liam Delaney & Colm Harmon & Cathy Remond
2010 Size Metrics and Dynamics of Firms Expansion in the European Pharmaceutical Industry
by Franco Mariuzzo & Xiaoheng Zhang
2010 External Price Benchmarking vs. Price Negotiation for Pharmaceuticals
by Philipp Ackermann
2010 The Study Of Biochemical Parameters For Naval Academy Team In The Naval Pentathlon
by Virgil ENE-VOICULESCU & Carmen ENE-VOICULESCU
2010 Trade and Innovation: Report on the Chemicals Sector
by Nobuo Kiriyama
2010 Margins and Market Shares:Pharmacy Incentives for Generic Substitution
by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume
2010 La structure sociale de l’industrie des biotechnologies en France: une étude des relations inter-organisationnelles au niveau inter-individuel
by Pina-Stranger, Alvaro
2010 Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century After the 1984 Waxman-Hatch Legislation
by Ernst R. Berndt & Murray L. Aitken
2010 Pricing and Reimbursement in U.S. Pharmaceutical Markets
by Ernst R. Berndt & Joseph P. Newhouse
2010 Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?
by Mark Trusheim & Murray L. Aitken & Ernst R. Berndt
2010 Has medical innovation reduced cancer mortality?
by Frank R. Lichtenberg
2010 Success in Pharmaceutical Research: The Changing Role of Scale and Scope Economies, Spillovers and Competition
by Tatiana Plotnikova
2010 Productivity and Heterogeneous Knowledge: Exploring the Relationship in a Sample of Drug Developers
by Giulio Bottazzi & Tatiana Plotnikova
2010 Inferring the Effects of Vertical Integration from Entry Games : An Analysis of the Generic Pharmaceutical Industry
by Kubo, Kensuke
2010 The More You Spend, the More You Get? The Effects of R&D and Capital Expenditures on the Patenting Activities of Biotechnology Firms
by Roberta Piergiovanni & Enrico Santarelli
2010 R&D Portfolios and Pharmaceutical Licensing
by Junichi Nishimura & Yosuke Okada
2010 Margins and Market Shares: Pharmacy Incentives for Generic Substitution
by Brekke, Kurt Richard & Holmås, Tor Helge & Straume, Odd Rune
2010 The Battle for Patent Rights in Plant Biotechnology: Evidence from Opposition
by Schneider, Cédric
2010 Pricing and Reimbursement in U.S. Pharmaceutical Markets
by Berndt, Ernst R. & Newhouse, Joseph P.
2010 Political contributions to influence consumers: the example of the u.s. drug reimportation debate
by Anne Boring
2010 Determinants of PRO-industry interactions in pharmaceutical R&D: the case of Mexico
by Santiago-Rodriguez, Fernando & Dutrenit, Gabriela
2010 A History-Friendly Model of the Evolution of the Pharmaceutical Industry: Technological Regimes and Demand Structure
by Christian Garavaglia & Franco Malerba & Luigi Orsenigo & Michele Pezzoni
2010 Competition in the Pharmaceutical Industry: How do Quality Differences Shape Advertising Strategies?
by de Frutos, Maria-Angeles & Ornaghi, Carmine & Siotis, Georges
2010 Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment
by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume
2010 Longitudinal Analysis of Generic Substitution
by Dag Morten Dalen & Marilena Locatelli & Steinar Strøm
2010 The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France
by Frank Lichtenberg
2010 Alfred Marshall Lecture Intellectual Property Rights Protection in Developing Countries: The Case of Pharmaceuticals
by Pinelopi Koujianou Goldberg
2010 Risk and Risk Management in Chemical Industry
by Sanda VISAN
2010 The current biotechnology outlook in Malaysia
by Khairiah Salwa MOKHTAR & Ravi MAHALINGAM
2010 On the impact of trust on consumer willingness to purchase GM food:Evidence from a European survey
by Damien Rousselière & Samira Rousselière
2010 Application Of Solid-State Fermentation For Cellulase Enzyme Production Using Trichoderma Viride
by KIRO MOJSOV
2010 Reliability Assessment And Measures For Resource-Saving In Water Lifting Engine Systems In Uzbekistan
by OLEG GLOVATSKY & RUSTAM ERGASHEV & BAKHTIER URALOV & HOLMATZHAN ISAKOV
2010 The Effects Of Inorganic Salts On Biosynthesis Of Pectinolytic Enzymes By Aspergillus Niger
by KIRO MOJSOV &
2010 The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation
by Guy David & Sara Markowitz & Seth Richards-Shubik
2010 Modern Medicine and the Twentieth Century Decline in Mortality: Evidence on the Impact of Sulfa Drugs
by Seema Jayachandran & Adriana Lleras-Muney & Kimberly V. Smith
2010 Network Effects in Biology R&D
by Joachim Henkel & Stephen M. Maurer
2010 Computer Mediated Transactions
by Hal R. Varian
2010 The Effect of Medicare Part D on Pharmaceutical Prices and Utilization
by Mark Duggan & Fiona Scott Morton
2010 Price Indexes, Inequality, and the Measurement of World Poverty
by Angus Deaton
2010 Contractibility and the Design of Research Agreements
by Josh Lerner & Ulrike Malmendier
2010(XX) Current Perspectives and Challenges of Biofuel Production and Consumption
by VICTOR PLATON & SIMONA FRONE & ANDREEA CONSTANTINESCU & SORINA JURIST
2009 Does Increased Price Competition Affect Entry of New Pharmaceutical Products?
by Granlund, David & Rudholm, Niklas
2009 Price and welfare effects of a pharmaceutical substitution reform
by Granlund, David
2009 Submarket Dynamics and Innovation: The Case of the U.S. Tire Industry
by Guido Buenstorf & Steven Klepper
2009 ¿A quién beneficia el comercio paralelo de medicamentos en la Unión Europea?
by Costa-Font, Joan & Kanavos, Panos
2009 Patenting activity in biotechnology and pharmaceuticals: a comparative analysis of the Nordic Countries
by Enrico Sorisio
2009 How variable is labor input in the Italian manufacturing: the case of the pharmaceutical industry
by Lorenzo Carbonari
2009 Of Patents and Property
by James Bessen & Michael J. Meurer
2009 Acceptance of biotechnology and social-cultural implications in Ghana
by Quaye, Wilhemina & Yawson, Ivy & Yawson, Robert M. & Williams, Irene E.
2009 The U.S. Seed Industustustry: An Exploration of Statistics Highlighting the Economic Cctivity of the U.S. Row Crop Seed Industry
by Maud Roucan-Kane & Allan Gray
2009 Impact de la réforme de l’assurance maladie en Tunisie sur l’offre et la demande des médicaments
by Ayadi, Inès
2009 Transfert technologique et processus collectif d'apprentissage dans l'industrie des biotechnologies en France
by Pina-Stranger, Alvaro
2009 Investments in Pharmaceuticals Before and After TRIPS
by Margaret Kyle & Anita McGahan
2009 Technology, Competition and the Time of Entry: Diversification Patterns in the Development of New Drugs
by Tatiana Plotnikova
2009 Technological Diversity and Future Product Diversity in the Drug Industry
by Uwe Cantner & Tatiana Plotnikova
2009 Evolution 1998-2002 of the antidepressant consumption in France, Germany and the United Kingdom
by Nathalie Grandfils & Catherine Sermet
2009 What’s on the Table? The Doha Round as of August 2009
by Matthew Adler & Claire Brunel & Gary Clyde Hufbauer & Jeffrey J. Schott
2009 Surgimiento de actividades de exportación exitosas en México: tres casos específicos
by Edgar Aragon & Anne Fouquet & Marcia Campos
2009 Surgimiento de actividades de exportación exitosas en Uruguay: cuatro casos específicos
by Michele Snoeck & Lucia Pittaluga & Hector Pastori & Rosario Domingo & Carlos Casacuberta
2009 The Emergence of Successful Export Activities in Uruguay: Four Case Studies
by Michele Snoeck & Lucia Pittaluga & Hector Pastori & Rosario Domingo & Carlos Casacuberta
2009 Surgimiento de nuevas actividades de exportación en América Latina: el caso de Chile
by Manuel Agosin & Claudio Bravo-Ortega
2009 The Emergence of New Successful Export Activities in Latin America: The Case of Chile
by Manuel Agosin & Claudio Bravo-Ortega
2009 The Emergence of Successful Export Activities in Mexico: Three Case Studies
by Edgar Aragon & Anne Fouquet & Marcia Campos
2009 Price and welfare effects of a pharmaceutical substitution reform
by Granlund, David
2009 Finance and Industrial Dynamics (In French)
by Claude DUPUY (GREThA UMR CNRS 5113) & Matthieu MONTALBAN (GREThA UMR CNRS 5113) & Sylvain MOURA (GREThA UMR CNRS 5113)
2009 How financialisation shapes productive models in pharmaceutical industry: the domination and contradictions of the blockbuster conception of control (In French)
by Matthieu MONTALBAN ( (GREThA UMR CNRS 5113)
2009 How financialisation shapes productive models in pharmaceutical industry: the domination and contradictions of the blockbuster conception of control (In French)
by Matthieu MONTALBAN (GREThA-GRES)
2009 Entry in the ADHD drugs market: Welfare impact of generics and me-toos AbstractRecent years have seen the growing popularity of drugs designed to treat attention deficit hyperactivity disorder (ADHD), and the number of patients, scripts, and revenues has been steadily increasing. By the mid-1990s there were already several branded drugs marketed for this disorder, as well as numerous generic formulations. With the expansion of the market in the late 1990s and early 2000s, new formulations (the so called `me-too' drugs) entered and caused dramatic changes in the distribution of market shares among available drugs. Using detailed sales data on psychostimulant drugs used to treat ADHD, we are able to identify and measure substitution patterns across a range of drugs. We find that the demand for ADHD drugs is fairly elastic and there are significant substitution possibilities among these drugs. Using estimates from demand parameters, we show that the first-time introduction of a generic drug can have large welfare gains due to the expansion of the market to price sensitive consumers. Additionally, the welfare gains due to the introduction of me-too drugs vary by the novelty of the drug, and for significantly new varieties can be larger than those of the introduction of a generic. Our results bear policy implications for both the speed with which new drugs are approved for marketing as well as for actions among pharmaceutical firms that may delay the entry of a generic drug
by Farasat A.S. Bokhari & Gary M. Fournier
2009 An Analysis of the Pricing of Traits in the U.S. Corn Seed Market
by Shi, Guanming & Chavas, Jean-Paul & Steigert, Kyle
2009 An Analysis of Bundle Pricing in Horizontal and Vertical Markets: The Case of the U.S. Cottonseed Market
by Shi, Guanming & Stiegert, Kyle & Chavas, Jean-Paul
2009 On Pricing and Vertical Organization of Differentiated Products
by Shi, Guanming & Chavas, Jean-Paul
2009 Biofuels: Players and discussions in Latin America
by Mariana Saidón
2009 Innovation Co-Operation Modes In Hungarian Chemical Industry
by BEATRIX LANYI
2009 Small is beautiful: deutsche Chemieunternehmen schrumpfen sich produktiv
by Oleg Badunenko
2009 R&D offshoring and clustering dynamics in pharmaceuticals and biotechnology: key features and insights from the Chinese case
by Abdelillah Hamdouch & Feng He
2009 The Effect of GDP Growth on Pharmaceutical Patent Protection, 1945-2005
by Summer La Croix & Ming Liu
2008 The Tunisian Pharmaceutical Sector in Transformation: Inventory of Fixtures and Innovation Prospects
by Nejla Yacoub
2008 Stratégies d’innovation des firmes des sciences de la vie et appropriation des ressources végétales : processus et enjeux Innovations strategies of firms in life science and appropriation of vegetal resources : process and stakes
by Blandine Laperche
2008 La lutte anti-blanchiment dans le secteur de l’assurance (the fight against money laundering in the insurance sector)
by Éric Vernier & Hubert Delval
2008 Consumer Learning and Heterogeneity: Dynamics of Demand for Prescription Drugs after Patent Expiration
by Ching, Andrew
2008 Policy options of agricultural biotechnology R&D in Sub-Saharan Africa: key issues and aspects
by Yawson, Robert M. & Yawson, Ivy
2008 Firm dynamic governance of global innovation by means of flexible networks of connections
by Gay, Brigitte
2008 Overcoming Innovation Limits through Outward FDI: The Overseas Acquisition Strategy of Indian Pharmaceutical Firms
by Pradhan, Jaya Prakash
2008 Regulation, generic competition and pharmaceutical prices: Theory and evidence from a natural experiment
by Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume
2008 Stratégies de R et D et innovation dans l’industrie pharmaceutique en France : une étude économétrique sur données individuelles
by Zouikri, Messaoud
2008 Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy
by Vincenzo Atella & Jay Bhattacharya & Lorenzo Carbonari
2008 Effects of Regulation on Drug Launch and Pricing in Interdependent Markets
by Patricia M. Danzon & Andrew J. Epstein
2008 Drug price setting and regulation in France
by Nathalie Grandfils
2008 Home to Market: Response,Resurgence and Transformation of Ayurveda from 1830's to 1920
by M.S. Harilal
2008 Genetic Codes of Mergers, Post Merger Technology Evolution and Why Mergers Fail
by Alexander Cuntz
2008 Generic Substitution
by Furu, Kari & Dalen, Dag Morten & Locatelli, Marilena & Strøm, Steinar
2008 Multinationals in the Knowledge Economy - a case study of AstraZeneca in Sweden
by Andersson, Martin & Johansson, Börje & Karlsson, Charlie & Lööf, Hans
2008 The European Socio-Economic Models of a Knowledge-based society. \r\nMain findings and conclusion \r\n
by Bruno AMABLE (Université Paris I and CEPREMAP) & Yannick LUNG (GREThA UMR CNRS 5113 and GERPISA)
2008 The European Socio-Economic Models of a Knowledge-based society. Main findings and conclusions
by Bruno AMABLE (Université Paris I and CEPREMAP) & Yannick LUNG (GREThA-GRES)
2008 Intellectual property rights in agricultural and agro-food biotechnologies to 2030 (© OECD International Futures Programme)
by Trommetter, M.
2008 Innovation in India and China : Challenges and Prospects in Pharmaceuticals and Biotechnology
by Jayan Jose Thomas
2008 On the Effects of Suggested Prices in Gasoline Markets
by Riemer P. Faber & Maarten C.W. Janssen
2008 Pharmaceutical Research Strategies
by Sandra Phlippen & An Vermeersch
2008 Internationalising to create Firm Specific Advantages: Leapfrogging strategies of U.S. Pharmaceutical firms in the 1930s and 1940s & Indian Pharmaceutical firms in the 1990s and 2000s
by Athreye, Suma & Godley, Andrew
2008 Experimentation with Strategy and the Evolution of Dynamic Capability in the Indian Pharmaceutical Sector
by Athreye, Suma & Kale, Dinar & Ramani, Shyama V.
2008 New Europe's Promise for Life Sciences
by Filippov, Sergey & Kalotay, Kalman
2008 Facing the Trial of Internationalizing Clinical Trials to Developing Countries: Some Evidence from Mexico
by Santiago-Rodriguez, Fernando
2008 A hybrid methodology for the Cox proportional hazard model
by Marianela Luzardo Briceño
2008 Geographic and Temporal Heterogeneity in Public Prescription Pharmaceutical Expenditures in Spain
by Lauridsen, Jorgen & Bech, Mickael & Lopez, Fernando & Mate Sanchez, Mariluz
2008 Selbstselektion statt Personalauswahl? Auslandsentsendungen in der deutschen chemischen Industrie
by Heiner Minssen & Susanne Schmidt
2008 The Determinants of Capital Structure of the Chemical Industry in Pakistan
by Muhammad Rafiq & Asif Iqbal & Muhammad Atiq
2008 Critical Success Factors for Intra-Disciplinary Transformation of the Agricultural Biotechnology Industry in Taiwan based on the Value Chain Concept
by Meng-Shiunn Lee
2008 Course technologique et valeur boursière. Une étude d'événements basée sur l'industrie pharmaceutique
by Sandy Campart & Étienne Pfister
2007 Positionierung der deutschen Industrie im globalen Konsolidierungsprozess : im Auftrag des Bundesministeriums für Wirtschaft und Technologie
by Michael Reinhard & Hans Schedl & Achim Buchwald & Ralph Henger
2007 Exploring the relationship between scientist human capital and firm performance: The case of biomedical academic entrepreneurs in the SBIR program
by Czarnitzki, Dirk & Toole, Andrew A.
2007 Restructuring of Energy-intensive Industrial Branches in Romania and Proposals for Industrial Policy Measures
by Edward Christie & Gabor Hunya & Waltraut Urban
2007 Generic entry into a regulated pharmaceutical market
by Iván Moreno Torres & Jaume Puig & Joan-Ramon Borrell-Arqué
2007 Multimarket contact in pharmaceutical markets
by Javier Coronado & Sergi Jiménez-Martín & Pedro L. Marín
2007 The determinants of pricing in pharmaceuticals: Are U.S. prices really higher than those of Canada?
by Antonio Cabrales & Sergi Jiménez-Martín
2007 Generic entry into a regulated pharmaceutical market
by Iván Moreno Torres & Jaume Puig & Joan-Ramon Borrell-Arqué
2007 Brevet, innovation modulaire et collaboration : Le cas des vaccins géniques
by Antoine Bureth & Moritz Mueller & Julien Pénin & Sandrine Wolff
2007 The Emergence of new Successful Export Activities in Uruguay
by Michele Snoeck & Carlos Casacuberta & Rosario Domingo & Héctor Pastori & Lucía Pittaluga
2007 Simulaatio lääkekehitysalan kannattavuudesta ja riskeistä
by Hermans, Raine & Kulvik, Martti
2007 Imposing a unilateral carbon constraint on European energy-intensive industries and its impact on their international competitiveness - data & analysis
by Bergmann, Manfred & Schmitz, Andreas & Hayden, Mark & Kosonen, Katri
2007 Betweenness Centrality of Fractal and Non-Fractal Scale-Free Model Networks and Tests on Real Networks
by Kitsak, Maksim & Havlin, Shlomo & Paul, Gerald & Riccaboni, Massimo & Pammolli, Fabio & Stanley, H. Eugene
2007 Financial Risk in the Biotechnology Industry
by Joseph H. Golec & John A. Vernon
2007 Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration
by Glenn Ellison & Sara Fisher Ellison
2007 Effects of 'Authorized-Generics' on Canadian Drug Prices
by Paul Grootendorst
2007 The Relationship among innovative Output, Productivity, and Profitability. A test comparing USPTO and EPO data
by Enrico Santarelli & Francesca Lotti
2007 Economic Policy in Health Care: Sickness Absence and Pharmaceutical Cost
by Granlund, David
2007 Consumer Information and Pharmaceutical Prices: Theory and Evidence
by Granlund, David & Rudholm, Niklas
2007 Consumer Information and Pharmaceutical Prices: Theory and Evidence
by Granlund, David & Rudholm, Niklas
2007 Incrementalism of environmental innovations versus paradigmatic change: A comparative study of the automotive and chemical industries
by Vanessa OLTRA (GREThA) & Maïder SAINT JEAN (GREThA)
2007 Incrementalism of environmental innovations versus paradigmatic change: A comparative study of the automotive and chemical industries
by Vanessa OLTRA (GREThA-GRES) & Maïder SAINT JEAN (GREThA-GRES)
2007 Flexibility in the implementation of intellectual property rights in agricultural biotechnology
by Trommetter, M.
2007 Indian Innovation Systems and Emergence of Biopharmaceutical Sector : Issues and Prospects
by Sachin Chaturvedi
2007 Downsizing in German Chemical Manufacturing Industry during the 1990s: Why Small Is Beautiful?
by Oleg Badunenko
2007 Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?
by Kurt R. Brekke & Astrid L. Grasdal & Tor Helge Holmås
2007 The Determinants of Pricing in Pharmaceuticals: Are U.S. prices really higher than those of Canada?
by Antonio Cabrales & Sergi Jiménez-Martín
2007 Multimarket Contact in Pharmaceutical Markets
by Javier Coronado & Sergi Jiménez-Martín & Pedro L. Marín
2007 Multimarket Contact in Pharmaceutical Markets
by Javier Coronado & Sergi Jiménez-Martín & Pedro L. Marín
2007 The Determinants of Pricing in Pharmaceuticals: Are U.S. Prices Really Higher than Those of Canada?
by Antonio Cabrales & Sergi Jiménez-Martín
2007 What is "Business Development"? - The Case of Biotechnology
by Sonja Kind & Dodo zu Knyphausen-Aufseß
2007 Les déterminants des fusions-acquisitions. Le cas de l'industrie pharmaceutique
by Gautier Duflos & Étienne Pfister
2006 Allocative efficiency measurement revisited: do we really need input prices?
by Badunenko, Oleg & Fritsch, Michael & Stephan, Andreas
2006 Überwindung betriebswirtschaftlicher Defizite im Innoregio-Netzwerk Kunststoffzentrum Westmecklenburg
by Neunteufel, Herbert & Rössel, Gottfried & Sassenberg, Uwe & Laske, Michael & Kipura, Janine & Brüning, Andreas
2006 Allocative efficiency measurement revisited: Do we really need input prices?
by Badunenko, Oleg & Fritsch, Michael & Stephan, Andreas
2006 Knowledge-sourcing strategies for cross-disciplinarity in bionanotechnology
by Isamel Rafols & Martin Meyer
2006 Riskirahoituksen merkitys biotekniikka-alalla: Pääomasijoittajien vertailu yritysten näkökulmasta
by Luukkonen, Terttu & Maunula, Mari
2006 Adaption of New Technologies and Costs of Health Care
by Kulvik, Martti & Linnosmaa, Ismo & Hermans, Raine
2006 Coaching Small Biotech Companies into Success: The Value-adding Function of VC
by Terttu Luukkonen, & Mari Maunula,
2006 The Perceived Value-added of Venture Capital Investors. Evidence from Finnish Biotechnology Industry
by Maunula, Mari
2006 Helsingin seudun klusterit sekä erikoistuminen bioteknologiaan ja logistiikkaan
by Hernesniemi, Hannu & Kulvik, Martti
2006 A Generalized Preferential Attachment Model for Business Firms Growth Rates: I. Empirical Evidence
by Pammolli, Fabio & Fu, Dongfeng & Buldyrev, Sergey V. & Riccaboni, Massimo & Matia, Kaushik & Yamasaki, Kazuko & Stanley, H. Eugene
2006 A Generalized Preferential Attachment Model for Business Firms Growth Rates: II. Mathematical Treatment
by Buldyrev, Sergey V. & Pammolli, Fabio & Riccaboni, Massimo & Yamasaki, Kazuko & Fu, Dongfeng & Matia, Kaushik & Stanley, H. Eugene
2006 Global Competitiveness of Indian Pharmaceutical Industry: Trends and Strategies
by Pradhan, Jaya Prakash
2006 Overseas Acquisition versus Greenfield Foreign Investment: Which Internationalization Strategy is better for Indian Pharmaceutical Enterprises?
by Pradhan, Jaya Prakash & Alakshendra, Abhinav
2006 Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research
by Jeffrey L. Furman & Margaret K. Kyle & Iain M. Cockburn & Rebecca Henderson
2006 Openness and Industrial Responses in a Wal-Mart World: A Case Study of Mexican Soaps, Detergents and Surfactant Producers
by Beata Smarzynska Javorcik & Wolfgang Keller & James R. Tybout
2006 Did Medicare Induce Pharmaceutical Innovation?
by Daron Acemoglu & David Cutler & Amy Finkelstein & Joshua Linn
2006 R&D in the Belgian Pharmaceutical Sector
by Helga De Doncker
2006 Jüngere Entwicklungen auf dem Risikokapitalmarkt für Biotechnologie in Deutschland
by Simeon Schudy
2006 Indian Patent Policy and Publich Health : implications from the Japanese Experience
by Aoki, Reiko & Kubo, Kensuke & Yamane, Hiroko
2006 The Pharmacia Story of Entrepreneurship and as a Creative Technical University - An Experiment in Innovation, Organizational Break Up and Industrial Renaissance
by Eliasson, Gunnar & Eliasson, Åsa
2006 Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?
by Brekke, Kurt R. & Grasdal, Astrid L. & Holmås, Tor Helge
2006 FDI and Spillover Effects in the Indian Pharmaceutical Industry
by Annika Bergman
2006 Allocative Efficiency Measurement Revisited: Do We Really Need Input Prices?
by Oleg Badunenko & Michael Fritsch & Andreas Stephan
2006 Indian Pharma Within Global Reach?
by Gehl Sampath, Padmashree
2006 Rough Road to Market: Institutional Barriers to Innovations in Africa
by Oyelaran-Oyeyinka, Banji & Gehl Sampath, Padmashree
2006 India's product patent protection regime: Less or more of "pills for the poor"?
by Gehl Sampath, Padmashree
2006 The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan
by Mahlich, Jörg C. & Roediger-Schluga, Thomas
2006 Breaking the Fence: Patent Rights and Biomedical Innovation in 'Technology Followers'
by Gehl Sampath, Padmashree
2006 The Dye Famine and its Aftermath: Knowledge Diffusion and Entry
by Genesove, David
2006 Reference Pricing of Pharmaceuticals
by Kurt R. Brekke & Ingrid Königbauer & Odd Rune Straume
2006 Research Strategies in Science-based Start-ups - Effects on performance in Danish and Swedish biotechnology
by Finn Valentin & Henrich Dahlgren & Rasmus Lund Jensen
2006 La propriété intellectuelle dans les biotechnologies agricoles : quels enjeux pour quelles perspectives ?
by Michel Trommetter
2006 Comment favoriser l'innovation dans le secteur pharmaceutique : brevets et/ou récompenses ?
by Paul Belleflamme & Tanguy van Ypersele
2006 Intégration technologique et valeur boursière des firmes de biotechnologies
by Lionel Nesta & Pier-Paolo Saviotti
2006 Biotechnologies et industrie pharmaceutique. Un modèle évolutionnaire conforme à l'histoire
by Franco Malerba & Luigi Orsenigo & Sandrine Selosse
2006 On the Life Cycle of Knowledge Intensive Sectors
by Thomas Grebel & Jackie Krafft & Pier-Paolo Saviotti
2006 The Evolution of Geographic Structure in New Industries
by Steven Klepper
2005 Does Public Scientific Research Complement Industry R&D Investment? The Case of NIH Supported Basic and Clinical Research and Pharmaceutical Industry R&D
by Toole, Andrew A.
2005 Public R&D Policy: The Right Turns of the Wrong Screw? The Case of the German Biotechnology Industry
by Fier, Andreas & Heneric, Oliver
2005 Functional Foods In The European Union: An Overview Of The Sector'S Main Issues
by Alessandra CASTELLINI & Maurizio Canavari & Carlo Pirazzoli
2005 Production of a New Drug: A Sequential Investment ProcessUnder Uncertainty
by Marcello Basili & Roberto Renò & Carlo Zappia
2005 Technological Characteristics and R&D Alliance Form: Evidence from the U.S. Biotechnology Industry
by Xia Wang
2005 Phases of Imitation and Innovation in a North-South Endogenous Growth Model
by Daniel Rais & Jonathan Goldman
2005 “Branded Generics” As A Strategy To Limit Cannibalization Of Pharmaceutical Markets
by Michael R. Ward & David Reiffen
2005 Innovation Paths of Estonian Biotechnology
by Tõnis Mets
2005 Consequences of the IPPC-directive’s BAT requirements for abatement costs and emissions
by Jan Larsson & Kjetil Telle
2005 The Growth of Business Firms: Theoretical Framework and Empirical Evidence
by Fu, Dongfeng & Pammolli, Fabio & Buldyrev, Sergey V. & Riccaboni, Massimo & Matia, Kaushik & Yamasaki, Kazuko & Stanley, H. Eugene
2005 Trips and Patenting Activity: Evidence from the Indian Pharmaceutical Industry
by Alka Chadha
2005 Product cycles, innovation and exports: A study of Indian pharmaceuticals
by Alka Chadha
2005 Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending
by Joseph Golec & Shantaram Hegde & John A. Vernon
2005 Socio-economic Impact of Nanoscale Science: Initial Results and NanoBank
by Lynne G. Zucker & Michael R. Darby
2005 Parallel Imports, Drag Price Control and Pharmaceutical Innovation
by Ken Tabata & Testuya Shinkai & Satoru Tanaka & Makoto Okamura
2005 Who Develops Innovations in Medicine for the Poor? Trends in Patent Applications Related to Medicines for HIV/AIDS, Tuberculosis, Malaria and Neglected Diseases
by Ito, Banri & Yamagata, Tatsufumi
2005 Testing Collusive Prices In A Multimarket Context: The European Case Of Vitamin C
by Jacint Balaguer & Ezequiel Uriel Jiménez & Vicente Orts
2005 Reference Pricing of Pharmaceuticals
by Brekke, Kurt R & Königbauer, Ingrid & Straume, Odd Rune
2005 Start-ups, firm growth and the consolidation of the French biotech industry
by Avenel, E. & Corolleur, F. & Gauthier, C. & Rieu, C.
2005 Knowledge and Productivity in the World's Largest Manufacturing Corporations Level:Panel Data analysis on Compustat and Patent data
by Lionel Nesta
2005 Biosafety Protocol, International Trade and Agricultural Biotechnology : Policy Inferences for India
by Sachin Chaturvedi & Lian Chawii
2005 State of Competition in the Wholesale and Retail Sector
by Ma. Teresa Dueñas-Caparas
2005 Empirical Tests of Optimal Cognitive Distance
by Wuyts, S.H.K. & Colombo, M. & Dutta, S. & Nooteboom, B.
2005 Density and Strength of Ties in Innovation Networks: An Analysis of Multi-Media and Biotechnology
by Gilsing, V.A. & Nooteboom, B.
2005 Generic Drug Industry Dynamics
by David Reiffen & Michael R. Ward
2005 Strategic Reasons for Patenting: Between Exclusion and Coordination Rationales
by Antoine Bureth & Rachel Levy & Julien Pénin & Sandrine Wolff
2004 Price Regulation and Competition in Japanese Pharmaceutical Market
by Tomofumi & Anegawa
2004 Biotechnology in New Zealand
by Dan Marsh
2004 Biotechnology in New Zealand
by Dan Marsh
2004 Regulatory ambivalence and the limitations of pharmaceutical policy in Spain
by Joan Costa & Jaume Puig
2004 Regulatory ambivalence and the limitations of pharmaceutical policy in Spain
by Joan Costa & Jaume Puig
2004 Estudios de competitividad sectoriales. Industria manufacturera
by María Inés Terra & Gustavo Bittencourt & Rosario Domingo & Carmen Estrades & Gabriel Katz & Alvaro Ons & Héctor Pastori
2004 Optimal Intellectual Property Rights Protection and Humanitarian Assistance during and International Health Emergency
by Drusilla K. Brown & George Norman
2004 Persistent Knowledge Specialisation and Intra-Industry Heterogeneity: an Analysis of the Spanish Pharmaceutical Industry
by Pablo D'Este Cukierman
2004 FDI spillovers and local productivity growth: evidence from Indian pharmaceutical industry
by Pradhan, Jaya Prakash
2004 Market Structure and Drug Innovation
by Pammolli, Fabio & Riccaboni, Massimo
2004 Dynamic Competition in Pharmaceuticals: Patent Expiry, Generic Penetration, and Industry Structure
by Magazzini, Laura & Pammolli, Fabio & Riccaboni, Massimo
2004 Preferential attachment and growth dynamics in complex systems
by Yamasaki, Kazuko & Matia, Kaushik & Buldyrev, Sergey V. & Fu, Dongfeng & Pammolli, Fabio & Riccaboni, Massimo & Stanley, H. Eugene
2004 The Effect of Drug Vintage on Survival: Micro Evidence from Puerto Rico's Medicaid Program
by Frank R. Lichtenberg
2004 Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process
by Ernst R. Berndt & Adrian H. B. Gottschalk & Tomas Philipson & Matthew W. Strobeck
2004 Vertical Product Differentiation, Market Entry, and Welfare
by Reisinger, Markus
2004 Competence in Health Care - An Industrial Systems Analysis Using Competence Bloc Theory to Compare European and US Health Care
by Eliasson, Gunnar & Eliasson, Åsa
2004 The Norwegian market for pharmaceuticals and the non-mandatory substitution reform of 2001: the case of enalapril
by Razzolini, Tiziano
2004 The Origin and Location of Entrants in the Evolution of the U.S. Tire Industry
by G. Buenstorf & S. Klepper
2004 A Dynamic Oligopoly Structural Model for the Prescription Drug Market After Patent Expiration
by Andrew Ching
2004 Las patentes aceleran o retrasan la comercializacion de nuevos medicamentos en los paises en desarrollo?
by Joan Ramon Borrell Arque
2004 Price Competition in Pharmaceuticals: The Case of Anti-infectives
by Steven N. Wiggins & Robert Maness
2004 La gouvernance des jeunes entreprises innovantes:un éclairage analytique à partir du cas des sociétés de biotechnologies
by Marc-Hubert Depret & Abdelillah Hamdouch
2004 L'interaction des dynamiques individuelles et collectives dans le processus de développement territorial
by Sophie-Hélène Bataïni
2003 Die Bedeutung von Patentschutz für den Technologietransfer in Entwicklungsländer : Erfahrungen der chemischen Industrie in Südkorea, Malaysia und Chile im Vergleich
by Thomas Röhm
2003 Das Marketingniveau in der Kunststoffbranche Westmecklenburgs
by Neunteufel, Herbert & Rössel, Gottfried & Sassenberg, Uwe
2003 International Price-Fixing Cartels and Developing Countries: A Discussion of Effects and Policy Remedies
by Margaret Levenstein & Valerie Suslow & Lynda Oswald
2003 Pharmaceutical generics, vertical product differentiation and public policy
by Antonio Cabrales
2003 Pharmaceutical generics, vertical product differentiation and public policy
by Antonio Cabrales
2003 Optimal Intellectual Property Rights Exhaustion and Humanitarian Assistance during a National Health Emergency
by Drusilla K. Brown & George Norman
2003 The Knowledge Bases of the World's Largest Pharmaceuticals Groups: what do Patent Citations to Non-Patent Literature Reveal?
by Stefano Brusoni & Paola Criscuolo & Aldo Geuna
2003 Intangible Assests and Market Value: Evidence from Biotechnology Firms
by Lionel Nesta & Pier-Paolo Saviotti
2003 Reverse Technology Transfer: A Patent Citation Analysis of the European Chemical and Pharmaceutical Sectors
by Paola Criscuolo
2003 The Effects of Environmental Regulation On Technology Diffusion: The Case of Chlorine Manufacturing
by Stavins, Robert & Snyder, Lori & Miller, Nolan
2003 Liberalization, Firm Size and R&D performance: A Firm Level Study of Indian Pharmaceutical Industry
by Pradhan, Jaya Prakash
2003 On Size and Growth of Business Firms
by De Fabritiis, Gianni & Riccaboni, Massimo & Pammolli, Fabio
2003 TRIPS and the Pharmaceutical Industry in Bangladesh: Towards a National Strategy
by Professor Tony VanDuzer
2003 Pharmaceutical Use and Expenditure for Cardiovascular Disease and Stroke: A Study of 12 OECD Countries
by Michael Dickson & Stéphane Jacobzone
2003 Uncertainty in the Generic Versus Brand Name Prescription Decision
by Hellström, Jörgen & Rudholm, Niklas
2003 Titanium Implants – A Comparison of a Swedish and an Ohio Firm
by Fridh, Ann-Charlotte
2003 Direct-to-Consumer Advertising in Pharmaceutical Markets
by Brekke, Kurt R. & Kuhn, Michael
2003 The Effects of Environmental Regulation on Technology Diffusion: The Case of Chlorine Manufacturing
by Lori Snyder & Nolan Miller & Robert Stavins
2003 Globalisation and Its Impact on Competitiveness: the Case of the British and German Pharmaceutical Industry
by Christel Lane & Jocelyn Probert
2003 Pharmaceutical Generics, Vertical Product Differentiation, and Public Policy
by Antonio Cabrales
2003 Reference prices: The Spanish way
by Jorge Mestre
2002 Erfolgsabhängige Vergütung: Ein sicherer Weg zur Steigerung der Leistung von Top-Managern?
by Zwick, Thomas & Wolf, Elke & Beblo, Miriam
2002 Does New Zealand have an Innovation System for Biotechnology?
by Dan Marsh
2002 Does New Zealand have an Innovation System for Biotechnology?
by Dan Marsh
2002 Economic Insights and Deficits in European Biotechnology Patent Policy
by Gilroy, Bernard Michael & Volpert, Tobias
2002 Economic Insights and Deficits in European Biotechnology Patent Policy
by Gilroy, Bernard Michael & Vollpert, Tobias
2002 A Comparison of U.S. and European University-Industry Relations in the Life Sciences
by Owen-Smith, Jason & Riccaboni, Massimo & Pammolli, Fabio & Powell, Walter W.
2002 Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as "equipment for your health"
by Frank R. Lichtenberg & Suchin Virabhak
2002 Benefits and Costs of Newer Drugs: An Update
by Frank Lichtenberg
2002 Innovation and Market Structure: An Empirical Evaluation of the 'Bounds Approach' in the Chemical Industry
by Marín Uribe, Pedro Luis & Siotis, Georges
2002 Biotecnologia: corporações, financiamento da inovação e novas formas organizacionais
by Silveira, José Maria F. J. da
2001 Innovation et marche financiers: l'impact des avancees therapeutiques sur les rentabilites boursieres des firmes
by Campart, S. & Pfister, E.
2001 Research Incentives in Competing Markets: A Model of the Development of New Vaccines
by Rey, P.
2001 The World Trade Organization and Publicly Funded Healthcare in Canada
by Ostry, A.
2001 Buying Science, Selling Drugs
by Evans, R.G. & Morgan, S.G. & Barer, M.L.
2001 Do court-ordered breakups spur innovation?
by Leon Taylor
2001 Modern Biotechnology in New Zealand: Further Analysis of Data from the Biotechnology Survey 1998/99
by Dan Marsh
2001 Modern Biotechnology in New Zealand: Further Analysis of Data from the Biotechnology Survey 1998/99
by Dan Marsh
2001 On Firm Growth in Networks
by Riccaboni, Massimo & Pammolli, Fabio
2001 Specialized technology suppliers, international spillovers and investment: evidence from the chemical industry
by Arora, Ashish & Fosfuri, Andrea & Gambardella, Alfonso
2001 An Empirical Model of Heterogeneous Consumer Search for Retail Prescription Drugs
by Alan T. Sorensen
2001 The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey
by Frank R. Lichtenberg
2001 Global/local articulation in industrial models for phamaceuticals, automobile and aeronautics (In French)
by Marie-Claude BÉLIS-BERGOUIGNAN (IFREDE-E3i) & Vincent FRIGANT (IFREDE-E3i) & Damien TALBOT (LEREPS)
2001 The Self-Organisation of Strategic Alliances
by Andreas Pyka & Paul Windrum
2001 Innovation Networks in the Biotechnology-Based Sectors
by Andreas Pyka & Paolo Saviotti
2000 How to win Schumpeterian Competition. Technological Transfers in the German Plastics Industry from the 1930s to the 1970s
by Streb, J.
2000 How to win Schumpeterian Competition. Technological Transfers in the German Plastics Industry from the 1930s to the 1970s
by Streb, J.
2000 Heternenous Labor Demand and Aggregate Job Flows. Specification, Estimation and Testing with French Data
by Fairise, X. & Feve, P.
2000 L'utilisation des notions de confiance et de proximite dans l'etude des processus de R&D pharmaceutiques
by Perrochon, D. & Lebert, D.
2000 Coalitions industrielles, reseaux de firmes et dynamiques de concurrence-cooperation dans les secteurs en cours de globalisation : le cas de l'industrie pharmaceutique
by Hamdouch, A. & Depret, M.-H.
2000 Fostering Innovation in a Small Open Economy: The Case of the New Zealand Biotechnology Sector
by Dan Marsh
2000 Fostering Innovation in a Small Open Economy: The Case of the New Zealand Biotechnology Sector
by Dan Marsh
2000 Heterogeneity in Returns to Scale: A Random Coefficient Analysis with Unbalanced Panel Data
by Erik Biørn & Kjersti-Gro Lindquist & Terje Skjerpen
2000 The Nature and the Extent of the Market for Technology in Biopharmaceuticals
by Arora, Ashish & Gambardella, Alfonso & Pammolli, Fabio & Riccaboni, Massimo
2000 Global Competitiveness in Pharmaceuticals: A European Perspective
by Gambardella, Alfonso & Orsenigo, Luigi & Pammolli, Fabio
2000 Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs
by Ernst R. Berndt & Robert S. Pindyck & Pierre Azoulay
2000 Entry and the Number of firms in the Swedish Pharmaceuticals Market
by Rudholm, Niklas
2000 Towards a History Friendly Model of Innovation, Market Structure and Regulation in the Dynamics of the Pharmaceutical Industry: the Age of Random Screening
by Franco Malerba & Luigi Orsenigo
2000 Corporate Governance and the Governance of Innovation: the Case of Pharmaceutical Industry
by Nicola Lacetera
2000 The determinants of pharmaceutical research and development expenditures
by Henry Grabowski & John Vernon
1999 An Examination of Technology Strategies for the Integration of Bioinformatics in Pharmaceutical R&D Processes
by Michael M. Hopkins
1999 Network Effects and Diffusion in Pharmaceutical Markets: Antiulcer Drugs
by Ernst R. Berndt & Robert S. Pindyck & Pierre Azoulay
1999 How to Win Schumpeterian Competition: Technological Transfers in the German Plastics Industry from the 1930s to the 1970s
by Jochen Streb
1998 Demand for Prescription Drugs: The Effects of Managed Care Pharmacy Benefits
by Rika Onishi Mortimer
1998 Characterizing Informational Barriers To Entry In The Anti-Ulcer Drug Market
by Matthew Shum
1998 Random Coefficients and Unbalanced Panels: An Application on Data from Norwegian Chemical Plants
by Erik Biørn & Kjersti-Gro Lindquist
1998 The Introduction of Pharmaceutical Product Patents in India: "Heartless Exploitation of the Poor and Suffering"?
by Jean O. Lanjouw
1998 The Impact of Generic Competition on Brand Name Market Shares - Evidence from Micro Data
by Aronsson, Thomas & Bergman, Mats & Rudholm, Niklas
1998 The Impact of Generic Competition on Brand Name Market Shares: Evidence from Micro Data
by Aronsson, Thomas & Bergman, Mats A. & Rudholm, Niklas
1998 Evolutionary innovations: learning, entrepreneurship and the dynamics of the firm
by Maureen McKelvey
1997 Foreign Direct Investment, Technological Capabilities and Performance in the Chinese Pharmaceutical Industry
by Steven White & Hideki Yoshihara & Xielin Liu
1997 Organizational Dynamics and Strcuture in the Chinese Pharmaceutical Industry: A Technological System Perspective
by Steven White
1997 Alternative Transition Trajectories for Complementary Asset Markets in China's Pharmaceutical Industry
by Steven White & Xielin Liu
1997 Outsourcing of Research by Pharmaceutical and Biotechnology Firms
by Tapon, F. & Thong, M.
1997 The Introduction of Pharmaceutical Product Patents in India: "Heartless Exploitation of the Poor and Suffering"?
by Lanjouw, J.O.
1997 The Pharmaceutical Industry in India and Hungary. Policies, Institutions, and Technological Development
by Felker, G. & Chaudhuri, S. & Gyorgy, K. & Goldman, M.
1997 Medicinal Plants, Rescuing Global Heritage
by Lambert, J. & Srivastava, J. & Vietmeyer, N.
1997 Les prestataires logistiques et la distribution pharmaceutique. Les barrieres a l'entree: vitres blindees ou glaces sans tain
by Mattiuzzo, N. & Le Goff, J.
1997 Merger, Retionalisation and the "High Commitment" Organisation
by Randle, K.
1997 Israel: Secteur de l'equipement medical
by Theriault, V.
1997 Chili:Secteur de l'equipement medical
by Froissart, S.
1997 Belgique: Secteur de l'equipement medical haute technologie
by Froissart, S.
1997 Thailande: Secteur de l'equipement medical
by Froissart, S.
1997 Malaisie: Secteur de l'equipement medical de haute technologie
by Froissart, S.
1997 The Strategic Response by Pharmaceutical Firms to the Medicaid Most-Favored-Customer Rules
by Fiona M. Scott Morton
1997 Royalty rates, sub licensing considerations and joint ventures
by Elli Malki
1997 The economic sense of royalty rates
by Elli Malki
1997 Intellectual property and the valuation of biotechnology
by Elli Malki
1997 Entry Decisions in the Generic Pharmaceutical Industry
by Fiona M. Scott Morton
1997 The Objectives of the FDA's Office of Generic Drugs
by Fiona Scott Morton
1997 Economic consequences of the German environmental liability act: Capital market response for the chemical industry
by Bartsch, Elga
1996 Characteristics of Demand for Pharmaceutical Products : an Examination of four Cephalosporins
by Ellison, S & Cockburn, I & Griliches, A & Hausman, J
1996 Rewarding Failure: Performance Related Pay in a Pharmaceutical research and Development Company
by Randle, K.
1995 R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
by Joseph A. Dimasi & Grabowski, Henry G. & Vernon, John
1995 Genotyping by Combinatorial Optimization Techniques
by Lancia, G.
1995 Generics and New Goods in Pharmaceutical Price Indexes
by Zvi Griliches & Iain Cockburn
1995 Do Other Firms Matter in Oligopolies?
by Haskel, Jonathan & Scaramozzino, Pasquale
1995 The transmission of information in the transacting of primary products: the case of quality improvement in Thailand's natural rubber production
by Shigetomi, Shinichi
1994 Fast Growing Small Entrepreneurial Firms and their Venture Capital Backers: an Applied Principal-Agent Analysis
by Gavin C Reid
1994 The Roles of Marketing, Product Quality and Price Competition in the Growth and Composition of the U.S. Anti-Ulcer Drug Industry
by Ernst R. Berndt & Linda Bui & David Reiley & Glen Urban
1993 Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry
by Rebecca Henderson & Iain Cockburn
1993 Pricing, Profits, and Technological Progress in the Pharmaceutical Industry
by F. M. Scherer
Overseas Acquisition Versus Greenfield Foreign Investment: Which Internationalization Strategy is better for Indian Pharmaceutical Enterprises?
by Jaya Prakash Pradhan & Abhinav Alakshendra
Global competitiveness of Indian Pharmaceutical Industry: Trends and Strategies
by Jaya Prakash Pradhan
Direct-to-Consumer Advertising in Pharmaceutical Markets
by Kurt R Brekke & Michael Kuhn
The impact of reference pricing system on brand name’s prices : the case of Tunisia
by Ayadi, Inès
Determinants of the United States’ trade of pharmaceuticals
by Boring, Anne
Investigating Generic and Brand Name Pharmaceutical’s Market Shares and Prices in Tunisia
by Chebbi, Houssem Eddine & Boujelbene, Younes & Ayadi, Inès
« Responsible Care» et management durable: comportement volontaire ou réaction adaptative ? Généalogie et pratiques dans l'industrie chimique
by Berland, Nicolas & Loison, Marie-Claire
Pharmaceutical Generics, Vertical Product Differentiation and Public Policy
by Cabrales, Antonio
